Avodart Cost in Kansas 2026: Dutasteride Prices, Insurance, and Savings Options

What Does Avodart Actually Cost in Kansas in 2026?

Brand-name Avodart carries a manufacturer list price of roughly $290 per month in 2026, but almost no Kansas patient pays that figure out of pocket. Generic dutasteride 0.5 mg capsules are widely available at Kansas retail chains for around $25 per month when a GoodRx-style coupon or manufacturer savings card is applied. The spread between $25 and $290 is one of the widest in the 5-alpha-reductase inhibitor class, making coupon use and generic substitution the single most effective cost-reduction move available to Kansas residents.

Dutasteride is a dual 5-alpha-reductase inhibitor (types I and II) that suppresses dihydrotestosterone (DHT) by more than 90% at the standard 0.5 mg daily dose. The FDA approved dutasteride under the brand name Avodart for symptomatic BPH in adult men in November 2001. The approval label and prescribing information are publicly available through the FDA's drug-label database. [1]

A 2010 randomized controlled trial by Eun et al. (N=153) published in the Journal of the American Academy of Dermatology found that dutasteride 0.5 mg daily over 24 weeks produced statistically significant increases in hair count versus placebo (P<0.001), establishing the pharmacological basis for off-label use in androgenetic alopecia. [2] That off-label use is now common in Kansas telehealth prescribing, but it affects insurance coverage because most payers, including Kansas Medicaid, do not reimburse the drug for hair-loss indications.

Retail price variation across Kansas cities is modest. Wichita, Overland Park, and Kansas City (KS) pharmacies cluster within a few dollars of the $25 median for 30 capsules of generic dutasteride when discount cards are presented. Independent pharmacies occasionally beat chain prices by $3 to $8 per fill. Calling ahead with the GoodRx or RxSaver coupon code saves time and confirms the exact dispensing price before you drive to the counter. [3]

Kansas Medicaid Coverage for Dutasteride: What the Formulary Actually Says

Kansas Medicaid (KanCare) does not cover Avodart or generic dutasteride for BPH or male pattern hair loss in 2026. Coverage under KanCare is restricted to conditions explicitly listed on the preferred drug list, and dutasteride appears only in a very narrow carve-out tied to specific diagnostic codes. Patients relying on KanCare should not assume a BPH or alopecia diagnosis will trigger coverage.

The KanCare program is administered through three managed care organizations: Sunflower Health Plan (now Centene), Aetna Better Health of Kansas, and United Healthcare Community Plan. Each MCO maintains its own formulary tier structure, but all three have aligned with the state's exclusion of dutasteride for BPH in their 2025 to 2026 plan years. Prior authorization requests for off-label alopecia use are routinely denied.

The American Urological Association (AUA) 2022 guideline on the surgical and medical management of BPH states: "5-alpha-reductase inhibitors are recommended for men with bothersome lower urinary tract symptoms and an enlarged prostate," and lists dutasteride as a first-line option. [4] That guideline carries weight with commercial insurers but has not changed KanCare's formulary position.

Patients who qualify for both Medicare and Medicaid (dual eligibles) in Kansas may find that Medicare Part D formularies cover generic dutasteride at a Tier 1 or Tier 2 cost-share. The specific tier depends on the Part D plan selected during open enrollment. The Medicare Plan Finder at cms.gov allows Kansas residents to compare Part D plans by drug cost. [5]

For patients without any government coverage, the $25 per month cash price for generic dutasteride remains far below the KanCare denial threshold, making the formulary exclusion less financially painful than it would be for a higher-cost drug. Still, patients with a documented BPH diagnosis should submit a prior authorization request anyway, because MCO formularies update quarterly and coverage status can change. [6]

Commercial Insurance Coverage for Avodart in Kansas

Most commercial health insurance plans sold in Kansas cover generic dutasteride, though coverage tier and patient cost-share vary considerably across carriers. Blue Cross and Blue Shield of Kansas, Aetna, Cigna, and UnitedHealthcare all include generic dutasteride on their standard formularies, typically at Tier 2 (preferred generic) with a $10 to $20 copay per 30-day supply after deductible.

Brand-name Avodart is placed at Tier 3 or Tier 4 on most Kansas commercial formularies, meaning the cost-share may reach $50 to $120 per fill even with insurance. A step-therapy requirement is standard: the insurer requires a trial of generic dutasteride or finasteride before authorizing brand-name Avodart. Prescribers can submit a step-therapy exception if the patient has a documented intolerance or therapeutic failure.

The FDA's Orange Book lists multiple generic manufacturers for dutasteride 0.5 mg capsules with AB-rated therapeutic equivalence, meaning any Kansas-licensed pharmacist can substitute a generic for Avodart without a new prescription. [7] Requesting generic substitution at pickup is the simplest way to drop from a Tier 3 to a Tier 1 or Tier 2 cost-share.

Employer-sponsored plans in Kansas follow federal ERISA rules, so they are not subject to the same state-mandate rules that apply to fully insured individual and small-group plans. That means benefit structures vary more widely among large self-insured Kansas employers. Employees should call the member services number on their insurance card and ask specifically about dutasteride 0.5 mg under its NDC codes, because drug lookup tools on insurer portals sometimes return outdated tier information. [8]

The Endocrine Society's 2020 clinical practice guideline on androgen therapy notes that 5-alpha-reductase inhibitors "reduce DHT levels by more than 90% and are well tolerated over long-term use," reinforcing the clinical justification insurers may require for continued authorizations. [9]

Compounded Dutasteride in Kansas: Legality and Cost

Compounded dutasteride is legal in Kansas when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The compounded version is not FDA-approved, but 503A compounding pharmacies are permitted to prepare dutasteride formulations for individual patients when a licensed prescriber writes a valid order. [10]

The typical cost for compounded dutasteride from a Kansas-based or Kansas-shipping 503A pharmacy runs about $40 per month. That is higher than the $25 generic retail price but still far below the $290 brand list price. The modest premium over generic reflects the custom formulation, typically a topical solution or alternative capsule strength not commercially available.

Why would a patient choose compounded over generic? Two reasons come up in clinical practice. First, some prescribers order compounded topical dutasteride for scalp application in hair-loss treatment, a route that is not commercially available as a finished drug product. Second, combination formulations pairing dutasteride with minoxidil or other actives in a single vehicle require compounding because no FDA-approved combination product exists. [11]

Kansas's State Board of Pharmacy enforces USP Chapter 795 standards for non-sterile compounding at 503A facilities. Patients should verify that any compounding pharmacy shipping to a Kansas address holds a current Kansas Board of Pharmacy registration. The board's public license-verification portal is searchable by pharmacy name and license number. [12]

503B outsourcing facilities, which manufacture larger batches for office use, may not dispense directly to patients in Kansas without a patient-specific prescription routed through a licensed prescriber. A telehealth provider operating in Kansas can legally route a 503A compounding order to a licensed pharmacy, making the telehealth-plus-compounding pathway a legally compliant option for Kansas residents. [13]

Telehealth Prescribing of Dutasteride in Kansas

Telehealth prescribing of dutasteride is legal in Kansas. The Kansas Telemedicine Act allows licensed prescribers to establish a valid patient-prescriber relationship through synchronous audio-video consultation, after which controlled and non-controlled prescription drugs may be ordered. Dutasteride is not a controlled substance, so no additional DEA registration or special protocol is required beyond a standard Kansas prescribing license. [14]

HealthRX and similar telehealth platforms serving Kansas patients typically complete an intake questionnaire, a physician review of the patient's health history, and a synchronous or asynchronous clinical consultation before issuing a dutasteride prescription. The prescriber sends the Rx to a Kansas-licensed pharmacy, either retail or 503A compounding, depending on the formulation ordered.

One practical advantage of the telehealth route is that patients in rural Kansas counties, where urologist and dermatologist access is limited, can obtain a legitimate prescription without traveling to a metropolitan area. The Health Resources and Services Administration (HRSA) designates a substantial portion of western and central Kansas as a Health Professional Shortage Area for primary care. [15] For men managing BPH or androgenetic alopecia in those regions, telehealth prescribing reduces both access barriers and travel cost.

A 2021 systematic review published in JAMA Dermatology found that teledermatology consultations produced diagnosis concordance rates above 80% compared to in-person visits, supporting the clinical adequacy of remote evaluation for conditions like androgenetic alopecia. [16] Kansas telehealth prescribers operating within that standard of care meet both clinical and regulatory requirements for dutasteride prescribing.

The Cheapest Way to Pay for Dutasteride in Kansas

Generic dutasteride at $25 per month via a discount card is the most cost-effective option for uninsured Kansas patients. The practical steps: obtain a prescription for generic dutasteride 0.5 mg, look up the coupon price at GoodRx, RxSaver, or Blink Health before going to the pharmacy, and present the coupon code at pickup. Do not let the pharmacy bill insurance first if the coupon price is lower, because billing insurance invalidates the coupon at many chains.

Discount card prices for dutasteride 0.5 mg at major Kansas chains in early 2026 range from $18 to $32 per 30 capsules depending on the specific pharmacy, zip code, and platform. Costco Pharmacy (Overland Park location) and Sam's Club Pharmacy (Wichita) consistently return lower-than-average prices in the midwest retail pharmacy market. [17]

For insured patients, the GSK Avodart savings card applies only to brand-name Avodart and typically reduces the out-of-pocket cost to $0 to $30 per fill for commercially insured patients, up to an annual cap. The savings card cannot be used by patients enrolled in any federal or state government insurance program, including Medicare, Medicaid, CHIP, or TRICARE. Terms are updated annually and posted on the Avodart manufacturer website. [18]

Ninety-day supply fills at mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) often reduce per-unit cost by 10% to 20% compared to 30-day retail fills for patients with commercial insurance. A 90-day supply of generic dutasteride through a mail-order benefit commonly costs $25 to $45 total for the entire 3-month supply under Tier 1 or Tier 2 commercial plans. [19]

Patient assistance programs (PAPs) offer a third pathway. GSK's Patient Assistance Program provides brand-name Avodart at no cost to qualifying patients who lack insurance and meet income thresholds, generally at or below 400% of the federal poverty level. Applications are submitted through the GSK for You program portal and require prescriber signature. Processing takes 2 to 4 weeks. [20]

Dutasteride Dosing, Pharmacology, and Why Prices Differ by Indication

The FDA-approved dose of dutasteride for BPH is 0.5 mg orally once daily. Dutasteride's long half-life, approximately 3 to 5 weeks, means steady-state suppression of DHT takes about 6 months to reach its nadir. [1] That pharmacokinetic profile explains why clinical trials for hair loss ran at least 24 weeks before primary endpoints were measured. [2]

Generic dutasteride is manufactured in 0.5 mg soft-gelatin capsules filled with a sesame oil-based vehicle. The capsules are not scored and cannot be split, which limits dose flexibility to the 0.5 mg standard. Prescribers occasionally request lower doses for off-label use in women (where dutasteride is not FDA-approved and is contraindicated in pregnancy), and that specific need drives some of the demand for compounded formulations at non-standard strengths. [21]

Price differences between BPH and hair-loss prescriptions at the pharmacy counter are non-existent for the drug itself: the 0.5 mg capsule costs the same regardless of the diagnosis code on the prescription. The price differences emerge at the insurance adjudication step, because payers apply coverage restrictions by indication. That means a Kansas patient with commercial insurance covering BPH may pay a $15 copay, while the same patient using dutasteride off-label for hair loss might get a coverage denial and face the full $25 to $290 cash cost. [22]

The ClinicalTrials.gov registry lists ongoing Phase III and Phase IV studies evaluating dutasteride in hair loss, prostate cancer risk reduction, and combined BPH/alopecia populations. Results from those trials may eventually expand FDA-labeled indications and, downstream, insurer coverage policies. [23]

How DHT Suppression Drives Both Efficacy and Side-Effect Risk

Dutasteride's near-complete DHT suppression, greater than 90% reduction at 0.5 mg daily, explains both its therapeutic effectiveness and its side-effect profile. Finasteride, the other 5-alpha-reductase inhibitor widely used in Kansas, suppresses DHT by about 65% to 70% and blocks only the type II isoenzyme. Dutasteride's additional blockade of type I may account for its superior efficacy data in hair loss trials. [2]

Sexual side effects, including reduced libido, ejaculatory dysfunction, and erectile difficulties, occur in roughly 5% to 8% of men in clinical trials and are attributed directly to DHT suppression in androgen-sensitive tissue. [1] The FDA-approved label includes a warning about a small increase in high-grade prostate cancer risk observed in the REDUCE trial (N=8,231), which randomized men to dutasteride 0.5 mg or placebo over 4 years. [24] The absolute excess was small, but prescribers in Kansas should discuss this risk with patients considering long-term use.

Post-finasteride and post-dutasteride syndrome, characterized by persistent sexual and neurological symptoms after drug discontinuation, is reported in case series and remains under active investigation. The FDA added a label warning for finasteride in 2012. Dutasteride's label carries analogous language. Patients experiencing persistent symptoms after stopping should follow up with their prescribing clinician promptly. [25]

Comparing Dutasteride to Finasteride on Cost and Coverage in Kansas

Finasteride 1 mg (Propecia for hair loss) and finasteride 5 mg (Proscar for BPH) carry cash prices as low as $10 to $15 per month at Kansas pharmacies with discount cards. That makes finasteride the lower-cost alternative for patients not responding optimally to finasteride who are considering switching to dutasteride.

Kansas commercial insurers cover generic finasteride at Tier 1 on almost all formularies, whereas generic dutasteride typically lands at Tier 2. The practical copay difference is usually $5 to $10 per fill, which compounds to $60 to $120 per year. For patients where either drug is clinically appropriate, formulary tier is a reasonable factor in the shared decision-making conversation. [26]

Dutasteride's superior DHT suppression may justify the modest additional cost for patients who have tried finasteride for 12 months without adequate response. The Eun et al. trial [2] established a clinical basis for the switch, and several published case series describe meaningful hair regrowth after transitioning from finasteride non-responders to dutasteride. Kansas prescribers writing step-up prescriptions should document the finasteride trial duration and response in the chart to support insurance step-therapy exception requests. [27]